Search 

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.

Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, and fintech spaces. a16z has nearly $16.5B in assets under management across multiple funds, including the $1.4B Bio funds, the $865M Crypto funds, and the Cultural Leadership Fund.

a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and who have domain expertise ranging from biology to crypto to distributed systems to security to marketplaces to financial services.

We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, and others in the technology ecosystem. We have built a network of experts including technical and executive talent; top media and marketing resources; Fortune 500/Global 2000 companies; as well as other technology decision makers, influencers, and key opinion leaders. a16z uses this network as part of our commitment to help our portfolio companies grow their business, so our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company building.

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.

Biotech

Charnwood Molecular is an award-winning, UK-based CRO, which has been providing expert synthetic chemistry support for over 20 years. At Charnwood Molecular, we work with clients of all shapes, sizes and global standing. These range across a variety of sectors, from virtual start-ups to established global agrochemical, materials chemistry, diagnostics, biotechnology and pharmaceutical companies. All of our clients benefit from our proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world.

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.

Liquid biopsy blood test for early detection of cancers